The Latest Breaking News from Boehringer Ingelheim

For decades, psychiatrists have treated psychosis as if it were separate conditions. People experiencing hallucinations and delusions might be diagnosed with schizophrenia, bipolar disorder, severe depression and related diagnoses, and receive completely different treatments based on diagnosis. But new research suggests this approach may be fundamentally flawed.

Silicosis is an incurable but entirely preventable lung disease. It has only one cause: breathing in too much silica dust. This is a risk in several industries, including tunnelling, stone masonry and construction.

In the fast-paced world of healthcare, where aging population and technological leaps are driving significant growth in the sector, which of the two medical stocks, Veeva Systems (VEEV) and Alcon Inc. (ALC), could emerge as the better prescription for your portfolio? Let's find out….

The controversial painkiller is being cited in a growing number of deaths in Spain despite warnings about dangerous side-effects

IBM is know for its huge developments in AI and quantum, and is now investigating applications outside of technology?

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Here's a roundup of top developments in the biotech space over the last 24 hours:

 Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…